Keryx Biopharmaceuticals (KERX) Shares are Down -39%

Keryx Biopharmaceuticals (KERX) : During the past 4 weeks, traders have been relatively bearish on Keryx Biopharmaceuticals (KERX), hence the stock is down -39.57% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -39.25% relative to the S&P 500. The 4-week change in the price of the stock is -38.07% and the stock has fallen -39% in the past 1 week.

Keryx Biopharmaceuticals (NASDAQ:KERX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.30 and $4.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.49, notching a gain of 6.65% for the day. The total traded volume was 2,137,280 . The stock had closed at $4.21 on the previous day.

The stock has recorded a 20-day Moving Average of 33.15% and the 50-Day Moving Average is 29.91%. Keryx Biopharmaceuticals Inc. has dropped 16.39% during the last 3-month period . Year-to-Date the stock performance stands at -11.09%.

Keryx Biopharmaceuticals (KERX) : The highest level Keryx Biopharmaceuticals (KERX) is projected to reach is $11 for the short term and the lowest estimate is at $4. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $8.14 and the possibility the share price can swing is $2.34.


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.